Emergent BioSolutions Inc (EBS)
9.48
+0.08
(+0.85%)
USD |
NYSE |
Nov 22, 16:00
9.41
-0.07
(-0.74%)
After-Hours: 20:00
Emergent BioSolutions Free Cash Flow: 138.10M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
September 30, 2024 | 138.10M |
June 30, 2024 | 37.60M |
March 31, 2024 | -132.20M |
December 31, 2023 | -257.90M |
September 30, 2023 | -209.40M |
June 30, 2023 | -358.70M |
March 31, 2023 | -279.50M |
December 31, 2022 | -149.90M |
September 30, 2022 | 63.20M |
June 30, 2022 | 126.60M |
March 31, 2022 | 77.60M |
December 31, 2021 | 96.10M |
September 30, 2021 | 22.90M |
June 30, 2021 | 120.90M |
March 31, 2021 | 310.40M |
December 31, 2020 | 395.00M |
September 30, 2020 | 271.90M |
June 30, 2020 | 194.00M |
March 31, 2020 | 51.30M |
December 31, 2019 | 101.10M |
September 30, 2019 | -171.50M |
June 30, 2019 | -5.20M |
March 31, 2019 | 65.70M |
December 31, 2018 | -30.30M |
September 30, 2018 | 221.37M |
Date | Value |
---|---|
June 30, 2018 | 95.63M |
March 31, 2018 | 119.33M |
December 31, 2017 | 153.30M |
September 30, 2017 | 55.62M |
June 30, 2017 | 43.54M |
March 31, 2017 | -24.19M |
December 31, 2016 | -21.60M |
September 30, 2016 | 0.955M |
June 30, 2016 | 81.68M |
March 31, 2016 | 96.62M |
December 31, 2015 | -2.295M |
September 30, 2015 | 43.53M |
June 30, 2015 | 26.42M |
March 31, 2015 | 40.52M |
December 31, 2014 | 81.64M |
September 30, 2014 | 46.92M |
June 30, 2014 | 13.04M |
March 31, 2014 | 33.42M |
December 31, 2013 | 54.95M |
September 30, 2013 | 1.986M |
June 30, 2013 | -1.38M |
March 31, 2013 | -18.02M |
December 31, 2012 | -14.20M |
September 30, 2012 | 54.78M |
June 30, 2012 | 5.619M |
Free Cash Flow Range, Past 5 Years
-358.70M
Minimum
Jun 2023
395.00M
Maximum
Dec 2020
30.96M
Average
70.40M
Median
Free Cash Flow Benchmarks
Abbott Laboratories | 6.486B |
Tonix Pharmaceuticals Holding Corp | -69.19M |
Geovax Labs Inc | -27.24M |
SIGA Technologies Inc | 71.46M |
Chimerix Inc | -70.42M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 153.70M |
Cash from Investing (Quarterly) | 112.00M |
Cash from Financing (Quarterly) | -180.30M |
Free Cash Flow Per Share (Quarterly) | 2.660 |
Free Cash Flow to Equity (Quarterly) | 347.50M |
Free Cash Flow to Firm (Quarterly) | 154.59M |
Free Cash Flow Yield | 27.42% |